Preclinical Research



Diabetic Preclinical Models

Approximately 29 million Americans alone carry a diagnosis of diabetes mellitus with approximatly 1.7 million new diagnosis each year in the United States alone. The prevalence worldwide is expected to reach 366 million by the year 2030. The increasing prevalance of diabetes is strongly connected to the increased prevalence of obesity. Diabetic patients have an increased risk factor of cardiovascular disease, stroke and renal diseaese. Type I Diabetes (T1D) is a result of immunological destruction of pancreatic beta-cells. Type 2 Diabetes (T2D) is the combination of impairment of insulin-mediated glucose disposal and defective secretion of insulin by pancreatic beta-cells. 


Common models for evaluating diabetic conditions include spontaneous models and chemically induced models. The non-obese diabetic (NOD) mouse model develops spontaneous autoimmune diabetes, which shares similarities with type 1 diabetes. The STZ-induced diabetic model involves an autoimmune process that results in the destruction of Langerhans islets. 


  • Fasting Glucose
  • GTT
  • Blood glucose level
  • C-peptide response
  • Food intake
  • Insulin
  • Histology
  • Protein/Creatinine
  • Biomarkers
  • Blood Pressure
  • Pain
Don't see the model or assessment you require? Our scientists are experienced with rapidly validating models from the literature. Please speak with a scientist to discuss your requirements. 




  • mouse NOD model
  • mouse STZ model
  • rat STZ model
  • pig STZ model


Request Study Proposal


+41-44 986-2628
email us